Literature DB >> 8826903

Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups.

D Menache1, D L Aronson, F Darr, R R Montgomery, J C Gill, C M Kessler, J M Lusher, P D Phatak, A D Shapiro, A R Thompson, G C White.   

Abstract

Nine patients (10 infusions) with a confirmed diagnosis of type 3 VWD were infused with von Willebrand factor (human), a preparation of von Willebrand factor (VWF) with a very low factor VIII content. Each patient was infused with one dose of approximately 50 or 100 iu ristocetin cofactor activity (VWF:RiCoF) per kg body weight. Bleeding times were performed during the 24 h period after infusion. Plasma samples were obtained over the 96 h period after infusion and were analysed for factor VIII coagulant activity (FVIIIC), VWF:RiCoF, von Willebrand factor antigen (VWF:Ag), and multimers. The FVIIIC data were analysed by non-linear least-squares analysis assuming constant FVIIIC 'synthesis' and exponential decay. The VWF data were fitted for exponential decay. The average decay rates for FVIIIC, VWF:RiCoF and VWF:Ag were 0.041, 0.061 and 0.056 respectively. The average calculated 'synthesis' rate for FVIIIC was 6.4 u/dl/h. The synthesis of FVIIIC was slightly faster and the decay slightly slower following the infusion of 100 iu VWF:RiCoF/kg than of 50 iu VWF:RiCoF/kg. Correction of the bleeding time was strongly dose dependent. At 4 h post infusion the median bleeding time was 9 min following a dose of 50 iu VWF:RiCoF/kg versus 3 min with a dose of 100 iu VWF:RiCoF/kg. There was no decrease in the bleeding time until the level of VWF:Ag or VWF:RiCoF reached > 100 u/dl.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826903     DOI: 10.1046/j.1365-2141.1996.d01-1860.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Functional Consequences of Mannose and Asialoglycoprotein Receptor Ablation.

Authors:  Yiling Mi; Marcy Coonce; Dorothy Fiete; Lindsay Steirer; Gabriela Dveksler; R Reid Townsend; Jacques U Baenziger
Journal:  J Biol Chem       Date:  2016-07-12       Impact factor: 5.157

2.  Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.

Authors:  Marco Campos; Ashley Buchanan; Fuli Yu; Maja Barbalic; Yang Xiao; Lloyd E Chambless; Kenneth K Wu; Aaron R Folsom; Eric Boerwinkle; Jing-fei Dong
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

Review 3.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Intracellular trafficking of factor VIII to von Willebrand factor storage granules.

Authors:  J B Rosenberg; P A Foster; R J Kaufman; E A Vokac; M Moussalli; P A Kroner; R R Montgomery
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

5.  Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.

Authors:  Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

6.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

7.  A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9.

Authors:  Jessica Garcia; Veronica H Flood; Sandra L Haberichter; Scot A Fahs; Jeremy G Mattson; Aron M Geurts; Mark Zogg; Hartmut Weiler; Qizhen Shi; Robert R Montgomery
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29

8.  Von Willebrand Factor Multimers and the Relaxation Response: A One-Year Study.

Authors:  Carlo Dal Lin; Laura Acquasaliente; Sabino Iliceto; Vincenzo De Filippis; Giuseppe Vitiello; Francesco Tona
Journal:  Entropy (Basel)       Date:  2021-04-10       Impact factor: 2.524

9.  In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor.

Authors:  Meaghan E Colling; Kenneth D Friedman; Walter H Dzik
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.